When was Conjustar founded?

Conjustar was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Conjustar located?

Conjustar is headquartered in Shanghai, China.

How many employees does Conjustar have?

As of Sep 30, 2026, the latest employee count at Conjustar is 1.

Is Conjustar a funded company?

Conjustar is a funded company, having raised a total of $27.8M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 21, 2022.

When was the latest funding round of Conjustar?

Conjustar's latest funding was a $***** Seed round on Jan 31, 2024, with participation from 3 investors. Its primary sector is Oncology. In China, the Oncology sector has seen $765M in funding in 2026 to date.

Where does Conjustar rank among its competitors?

Conjustar ranks 1514th amongst 3445 active competitors, of which 1140 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Conjustar?

Conjustar's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Conjustar - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drug conjugates for the treatment of cancer. The company is developing miniaturized drug conjugates such as peptide, nanobody drug conjugates, and PDC to conquer solid tumors.

Website: conjustar.com
Email ID: *****@conjustar.com
Phone Number: +86 **********

Key Metrics

Founded Year

2022

Location

Shanghai, China

Stage

Seed

Total Funding

$27.8M in 3 rounds

Latest Funding Round

Seed, Jan 31, 2024, $*****

Investors

Fosun Health Capital & 5 more

Ranked

1514^th among 3445 active competitors

Employee Count

1 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3094 more

View Conjustar's full profile

Conjustar has raised a total funding of $27.8M over 3 rounds. Its first funding round was on Feb 21, 2022. Its latest funding round was a Seed round on Jan 31, 2024 for $*****. 3 investors participated in its latest round. Conjustar has 6 institutional investors.

Here is the list of recent funding rounds of Conjustar:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 31, 2024	5272472	Seed	8856288	4255727	7533444	3948151
Feb 23, 2023	5608234	Angel	3138921	4357509	6573890	Tahoe Ventures & 1 more
Feb 21, 2022	3724517	Seed	6879935	4664347	Fosun Health Capital	8065409

Access funding benchmarks and valuations. Sign up today!

View details of Conjustar's funding rounds and investors

Conjustar's employee count trend

Conjustar has 1 employees as of Sep 26. Here is Conjustar's employee count trend over the years:

Uncover Conjustar's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Conjustar include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Conjustar, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
1514th	Conjustar 2022, Shanghai (China), Seed	Developer of drug conjugates for the treatment of cancer	$27.8M	Fosun Pharmaceutical, Tahoe Ventures & 4 others	34/100